Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.80
CLSN's Cash to Debt is ranked higher than
63% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. CLSN: 3.80 )
CLSN' s 10-Year Cash to Debt Range
Min: 0.16   Max: No Debt
Current: 3.8

Equity to Asset 0.49
CLSN's Equity to Asset is ranked higher than
62% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CLSN: 0.49 )
CLSN' s 10-Year Equity to Asset Range
Min: -5.59   Max: 0.96
Current: 0.49

-5.59
0.96
F-Score: 2
Z-Score: -3.82
M-Score: 3.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4943.00
CLSN's Operating margin (%) is ranked higher than
51% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. CLSN: -4943.00 )
CLSN' s 10-Year Operating margin (%) Range
Min: -163200   Max: -75.32
Current: -4943

-163200
-75.32
Net-margin (%) -5098.80
CLSN's Net-margin (%) is ranked higher than
51% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CLSN: -5098.80 )
CLSN' s 10-Year Net-margin (%) Range
Min: -151566.67   Max: -67.41
Current: -5098.8

-151566.67
-67.41
ROE (%) -67.38
CLSN's ROE (%) is ranked higher than
61% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. CLSN: -67.38 )
CLSN' s 10-Year ROE (%) Range
Min: -6771.43   Max: 257.55
Current: -67.38

-6771.43
257.55
ROA (%) -39.81
CLSN's ROA (%) is ranked higher than
65% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. CLSN: -39.81 )
CLSN' s 10-Year ROA (%) Range
Min: -727.9   Max: 121.96
Current: -39.81

-727.9
121.96
ROC (Joel Greenblatt) (%) -2660.39
CLSN's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. CLSN: -2660.39 )
CLSN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15483.87   Max: -114.68
Current: -2660.39

-15483.87
-114.68
Revenue Growth (3Y)(%) -58.80
CLSN's Revenue Growth (3Y)(%) is ranked higher than
57% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CLSN: -58.80 )
CLSN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -27.1
Current: -58.8

EBITDA Growth (3Y)(%) -35.70
CLSN's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CLSN: -35.70 )
CLSN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -57.5   Max: 39.1
Current: -35.7

-57.5
39.1
EPS Growth (3Y)(%) -34.90
CLSN's EPS Growth (3Y)(%) is ranked higher than
58% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CLSN: -34.90 )
CLSN' s 10-Year EPS Growth (3Y)(%) Range
Min: -48.2   Max: 30.5
Current: -34.9

-48.2
30.5
» CLSN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CLSN Guru Trades in Q1 2014

Chuck Royce 233,159 sh (+555.77%)
Jim Simons Sold Out
» More
Q2 2014

CLSN Guru Trades in Q2 2014

Chuck Royce 233,159 sh (unchged)
» More
Q3 2014

CLSN Guru Trades in Q3 2014

Jim Simons 49,964 sh (New)
Chuck Royce 233,159 sh (unchged)
» More
Q4 2014

CLSN Guru Trades in Q4 2014

Jim Simons 116,486 sh (+133.14%)
Chuck Royce 233,159 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CLSN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.68
CLSN's P/B is ranked higher than
92% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. CLSN: 1.68 )
CLSN' s 10-Year P/B Range
Min: 1.25   Max: 170.59
Current: 1.68

1.25
170.59
P/S 101.41
CLSN's P/S is ranked lower than
54% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. CLSN: 101.41 )
CLSN' s 10-Year P/S Range
Min: 2.24   Max: 760.5
Current: 101.41

2.24
760.5
EV-to-EBIT -1.13
CLSN's EV-to-EBIT is ranked higher than
56% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CLSN: -1.13 )
CLSN' s 10-Year EV-to-EBIT Range
Min: -9.4   Max: 0.3
Current: -1.13

-9.4
0.3
Current Ratio 3.72
CLSN's Current Ratio is ranked higher than
70% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CLSN: 3.72 )
CLSN' s 10-Year Current Ratio Range
Min: 0.08   Max: 22.76
Current: 3.72

0.08
22.76
Quick Ratio 3.72
CLSN's Quick Ratio is ranked higher than
71% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CLSN: 3.72 )
CLSN' s 10-Year Quick Ratio Range
Min: 0.06   Max: 22.73
Current: 3.72

0.06
22.73
Days Sales Outstanding 153.30
CLSN's Days Sales Outstanding is ranked higher than
71% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. CLSN: 153.30 )
CLSN' s 10-Year Days Sales Outstanding Range
Min: 4.2   Max: 2190
Current: 153.3

4.2
2190

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.33
CLSN's Price/Net Cash is ranked higher than
66% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. CLSN: 18.33 )
CLSN' s 10-Year Price/Net Cash Range
Min: 1.84   Max: 245.45
Current: 18.33

1.84
245.45
Price/Net Current Asset Value 15.27
CLSN's Price/Net Current Asset Value is ranked higher than
66% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. CLSN: 15.27 )
CLSN' s 10-Year Price/Net Current Asset Value Range
Min: 1.19   Max: 121.5
Current: 15.27

1.19
121.5
Price/Tangible Book 1.79
CLSN's Price/Tangible Book is ranked higher than
93% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. CLSN: 1.79 )
CLSN' s 10-Year Price/Tangible Book Range
Min: 1.05   Max: 222.75
Current: 1.79

1.05
222.75
Price/Median PS Value 3.58
CLSN's Price/Median PS Value is ranked higher than
64% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CLSN: 3.58 )
CLSN' s 10-Year Price/Median PS Value Range
Min: 0.19   Max: 5.05
Current: 3.58

0.19
5.05
Earnings Yield (Greenblatt) -88.50
CLSN's Earnings Yield (Greenblatt) is ranked lower than
71% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CLSN: -88.50 )
CLSN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -291.7   Max: 771.8
Current: -88.5

-291.7
771.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CBOB.Germany,
Celsion Corp is a Delaware corporation incorporated in 1982. The Company is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's product include ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). The Company's pipeline also includes GEN-1 a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence. It is also working to develop and commercialize oncology therapies based on its technologies by developing novel therapeutics for cancer treatment. The Company faces competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company's research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to regulation by the FDA and foreign regulatory agencies.
» More Articles for CLSN

Headlines

Articles On GuruFocus.com
Dead Biotech Plays Surge To Life May 07 2013 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 6,000 Shares Nov 19 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 5,000 Shares Aug 17 2009 
Celsion Reports Second Quarter 2009 Financial Results and Business Update Aug 05 2009 
Celsion to Hold Second Quarter 2009 Financial Results Jul 31 2009 
Celsion Corp. (CLSN) CEO Michael H Tardugno buys 3,750 Shares Mar 18 2009 
Celsion Corporation to Hold Conference Call to Discuss Its Announced Japan License Agreement for The Dec 16 2008 
Celsion Corporation Announces Exclusive Japan License Agreement with Yakult Honsha for ThermoDox® Dec 15 2008 

More From Our Partners
Celsion Gains on Impressive Breast Cancer Study Data - Analyst Blog Apr 16 2015 - ZACKS

More From Other Websites
Nasdaq stocks posting largest volume increases Apr 27 2015
Celsion Corporation Announces Appointment of Harriet Shelare to Director, Communications Apr 27 2015
Celsion Corporation Announces Appointment of Harriet Shelare to Director, Communications Apr 27 2015
Celsion Gains on Impressive Breast Cancer Study Data - Analyst Blog Apr 16 2015
Celsion (CLSN) Shows Strength: Stock Adds 18.6% in Session - Tale of the Tape Apr 16 2015
Celsion Announces Positive Interim Data from its Phase 2 DIGNITY Study in Breast Cancer Apr 15 2015
Celsion Announces Positive Interim Data from its Phase 2 DIGNITY Study in Breast Cancer Apr 15 2015
Celsion Corporation Reports Year End 2014 Financial Results and Provides Business Update Mar 19 2015
CELSION CORP Financials Mar 18 2015
CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 12 2015
Celsion Corporation Reports Year End 2014 Financial Results and Provides Business Update Mar 12 2015
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver... Mar 10 2015
Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12,... Mar 05 2015
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver... Feb 23 2015
UPDATE: Celsion Slightly Falls Back Following Treatment News Feb 20 2015
Celsion Jumps On Interim Data On Cancer Drug Feb 20 2015
Celsion Corporation Presents Clinical and Preclinical Data for GEN-1 IL-12 Immunotherapy in Ovarian... Feb 20 2015
Celsion Corporation Presents Clinical and Preclinical Data for GEN-1 IL-12 Immunotherapy in Ovarian... Feb 20 2015
CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Jan 20 2015
Celsion Corporation and myTomorrows Partner to Introduce ThermoDox® Early Access Program in Europe... Jan 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK